Coronavirus Pneumonia and Pulmonary Thromboembolism

Announcing a new publication for BIO Integration journal. In this article the authors Mingkang Yao; Phei Er Saw and Shanping Jiang from Sun Yat-Sen University, Guangzhou, China review Coronavirus Pneumonia and Pulmonary Thromboembolism.

In this review, the authors summarize the harmful effects of that coronavirus pneumonia and highlight the clinical relationship between PTE and coronavirus infection. Potential mechanisms and prophylaxis and therapeutic measures are also discussed.

The COVID-19 global pandemic has severely threatened public respiratory health and medical services. Coagulation disorders, especially pulmonary thromboembolism (PTE), has proved to be a complication in severe COVID-19 patients, with the incidence of PTE causing poor clinical outcome and increased fatality.

It is important that healthcare providers recognize that patients with COVID-19 are at increased risk of PTE, and ensure that appropriate prophylaxis is administered to the appropriate patients, and that they effectively manage PTE when it does occur.

The mechanism of PTE in patients with coronavirus pneumonia consists of endothelial injury, activated platelet, cytokine storm, and a suppressed fibrinolytic system. Early prophylaxis, antiviral therapy, anticoagulation, and supportive treatment are beneficial to COVID-19 patients.

In this review, the authors summarize the harmful effects of that coronavirus pneumonia and highlight the clinical relationship between PTE and coronavirus infection. Potential mechanisms and prophylaxis and therapeutic measures are also discussed.

Article reference: Mingkang Yao; Phei Er Saw and Shanping Jiang, Coronavirus Pneumonia and Pulmonary Thromboembolism, BIO Integration, 2020, https://doi.org/10.15212/bioi-2020-0030

BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.

BIOI is now open for submissions; articles can be submitted online at:

https://mc04.manuscriptcentral.com/bioi

Please visit www.bio-integration.org to learn more about the journal.

Editorial Board: https://bio-integration.org/editorial-board/

BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (www.bio-integration.org).

Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).

There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).

ISSN 2712-0074

eISSN 2712-0082